Vergoeding 2017-2021 voor ATC-subgroep J05AP : Antivirale middelen voor behandeling van hcv-infecties
- Raming voor de totale Zvw-populatie
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| J05AP01 Ribavirine | 148.220 | 85.125 | 75.357 | 37.675 | 12.852 |
| J05AP05 Simeprevir | 247.030 | 50.033 | . | . | . |
| J05AP07 Daclatasvir | 6.061.800 | 838.270 | 11.424 | . | . |
| J05AP08 Sofosbuvir (Sovaldi ®) | 11.079.800 | 2.240.200 | 197.790 | 189.850 | 100.710 |
| J05AP09 Dasabuvir | 59.635 | 4.186 | . | . | . |
| J05AP51 Sofosbuvir met ledipasvir (Harvoni ®) | 18.939.300 | 7.163.400 | 1.090.200 | 277.360 | 150.380 |
| J05AP53 Ombitasvir met paritaprevir en ritonavir | 822.040 | 84.546 | . | . | . |
| J05AP54 Elbasvir met grazoprevir (Zepatier ®) | 1.621.300 | 1.111.800 | 1.713.100 | 1.178.200 | 566.750 |
| J05AP55 Sofosbuvir met velpatasvir (Epclusa ®) | 11.147.100 | 14.334.200 | 5.040.800 | 2.126.600 | 1.771.900 |
| J05AP56 Sofosbuvir met velpatasvir en voxilaprevir (Vosevi ®) | . | 511.840 | 729.290 | 299.300 | 438.800 |
| J05AP57 Glecaprevir met pibrentasvir (Maviret ®) | . | 10.556.200 | 9.726.300 | 7.323.000 | 7.466.200 |
| Totaal | 50.126.225 | 36.979.800 | 18.584.261 | 11.431.985 | 10.507.592 |